CRISPR Therapeutics proved the strength of its technology a couple of years ago when it won approval for its first product.

Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...

Fort Collins, Colorado, Dec. 07, 2023 (GLOBE NEWSWIRE) -- According to DataHorizzon Research, The CRISPR Technology Market is expected to value USD 3.2 Billion in 2022 and is projected to reach USD 12 ...

Dublin, Aug. 06, 2024 (GLOBE NEWSWIRE) -- The "CRISPR Technology Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The crispr technology market size has grown ...

Charles Gersbach and his colleagues are pursuing promising CRISPR technologies focused on controlling gene activity rather ...

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...

A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday ...

The global CRISPR technology market is anticipated to grow at a robust compound annual growth rate of approximately 16% over the next five years. This rapid expansion is driven by continuous ...

CRISPR Therapeutics CRSP reported a first-quarter 2026 loss of $1.28 per share, wider than the Zacks Consensus Estimate of a loss of $1.14. The company had incurred a loss of $1.58 in the year-ago ...